Capital Increase in Genmab as a Result of Employee Warrant Exercise
June 25, 2019 12:42 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; June 25, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 9,577 shares as a consequence of the exercise of employee warrants. ...
Major Shareholder Announcement
June 19, 2019 11:36 ET
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; June 19, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish...
Major Shareholder Announcement
June 19, 2019 07:57 ET
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; June 19, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish...
Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38
June 11, 2019 01:48 ET
|
Genmab A/S
Company Announcement Genmab signs agreement with Janssen Biotech, Inc. to collaborate exclusively on next-generation CD38 antibody product, HexaBody®-CD38, incorporating Genmab’s proprietary HexaBody...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
June 06, 2019 16:38 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; June 6, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 6,464 restricted stock units and 21,343...
U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
May 30, 2019 17:07 ET
|
Genmab A/S
Company Announcement U.S. FDA grants Priority Review for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma...
Genmab Files Registration Statement in the United States for a Proposed Public Offering of American Depositary Shares (ADSs) and Applies for Listing of the ADSs on Nasdaq
May 28, 2019 16:32 ET
|
Genmab A/S
Company Announcement Genmab has today filed a registration statement with the U.S. Securities and Exchange Commission for the proposed public offering of ADSs and has applied for listing of the ADSs...
Genmab Announces Data to be Presented at 24th EHA Annual Congress
May 16, 2019 09:42 ET
|
Genmab A/S
Media Release Copenhagen, Denmark, May 16, 2019 15 industry-sponsored abstracts featuring Genmab programs selected for presentation at EHA Annual Congress Genmab A/S (Nasdaq Copenhagen: GEN)...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
May 14, 2019 15:37 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; May 14, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 9,737 shares as a consequence of the exercise of employee warrants. ...
Genmab Announces Financial Results for the First Quarter of 2019
May 08, 2019 11:01 ET
|
Genmab A/S
May 8, 2019; Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2019 Highlights Regulatory applications for daratumumab in combination with lenalidomide and dexamethasone...